• bioAffinity Technologies entered a nationwide federal healthcare distribution agreement with veteran-owned AvMEDICAL for its CyPath Lung cancer test.
• Deal targets expanded access across US government and agency healthcare systems via AvMEDICAL procurement channels, contracting expertise, customer relationships.
• Partnership debuted at the 2026 NAVREF Annual Conference, where the companies jointly presented CyPath Lung to more than 300 attendees.
• CyPath Lung is a noninvasive sputum-based test intended to complement imaging in lung cancer assessment, with focus on veteran screening needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930178247) on September 30, 2026, and is solely responsible for the information contained therein.